» Articles » PMID: 21483670

Spotlight on Differentially Expressed Genes in Urinary Bladder Cancer

Overview
Journal PLoS One
Date 2011 Apr 13
PMID 21483670
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: We previously identified common differentially expressed (DE) genes in bladder cancer (BC). In the present study we analyzed in depth, the expression of several groups of these DE genes.

Materials And Methods: Samples from 30 human BCs and their adjacent normal tissues were analyzed by whole genome cDNA microarrays, qRT-PCR and Western blotting. Our attention was focused on cell-cycle control and DNA damage repair genes, genes related to apoptosis, signal transduction, angiogenesis, as well as cellular proliferation, invasion and metastasis. Four publicly available GEO Datasets were further analyzed, and the expression data of the genes of interest (GOIs) were compared to those of the present study. The relationship among the GOI was also investigated. GO and KEGG molecular pathway analysis was performed to identify possible enrichment of genes with specific biological themes.

Results: Unsupervised cluster analysis of DNA microarray data revealed a clear distinction in BC vs. control samples and low vs. high grade tumors. Genes with at least 2-fold differential expression in BC vs. controls, as well as in non-muscle invasive vs. muscle invasive tumors and in low vs. high grade tumors, were identified and ranked. Specific attention was paid to the changes in osteopontin (OPN, SPP1) expression, due to its multiple biological functions. Similarly, genes exhibiting equal or low expression in BC vs. the controls were scored. Significant pair-wise correlations in gene expression were scored. GO analysis revealed the multi-facet character of the GOIs, since they participate in a variety of mechanisms, including cell proliferation, cell death, metabolism, cell shape, and cytoskeletal re-organization. KEGG analysis revealed that the most significant pathway was that of Bladder Cancer (p = 1.5×10(-31)).

Conclusions: The present work adds to the current knowledge on molecular signature identification of BC. Such works should progress in order to gain more insight into disease molecular mechanisms.

Citing Articles

Identification of SPP1 as a Prognostic Biomarker and Immune Cells Modulator in Urothelial Bladder Cancer: A Bioinformatics Analysis.

Nedjadi T, Ahmed M, Ansari H, Aouabdi S, Al-Maghrabi J Cancers (Basel). 2023; 15(23).

PMID: 38067407 PMC: 10705199. DOI: 10.3390/cancers15235704.


Hemimycale Arabica Induced Non-Cytotoxic Anti-Migratory Activity in Hepatocellular Carcinoma In Vitro.

Rady H, Hassan A, Abd-Alla H, Raouf H, Salem S Asian Pac J Cancer Prev. 2022; 23(9):2921-2928.

PMID: 36172653 PMC: 9810293. DOI: 10.31557/APJCP.2022.23.9.2921.


An Integrated Bioinformatics Analysis towards the Identification of Diagnostic, Prognostic, and Predictive Key Biomarkers for Urinary Bladder Cancer.

Sarafidis M, Lambrou G, Zoumpourlis V, Koutsouris D Cancers (Basel). 2022; 14(14).

PMID: 35884419 PMC: 9319344. DOI: 10.3390/cancers14143358.


A Novel Cyclic Pentadepsipeptide, -Methylsansalvamide, Suppresses Angiogenic Responses and Exhibits Antitumor Efficacy against Bladder Cancer.

Song J, Park J, Lyea Park S, Hwang B, Kim W, Lee C Cancers (Basel). 2021; 13(2).

PMID: 33430488 PMC: 7827157. DOI: 10.3390/cancers13020191.


Osteopontin accelerates the development and metastasis of bladder cancer via activating JAK1/STAT1 pathway.

Zhang N, Li F, Gao J, Zhang S, Wang Q Genes Genomics. 2020; 42(4):467-475.

PMID: 32088853 DOI: 10.1007/s13258-019-00907-6.


References
1.
van Rhijn B, Burger M, Lotan Y, Solsona E, Stief C, Sylvester R . Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol. 2009; 56(3):430-42. DOI: 10.1016/j.eururo.2009.06.028. View

2.
Churchill G . Fundamentals of experimental design for cDNA microarrays. Nat Genet. 2002; 32 Suppl:490-5. DOI: 10.1038/ng1031. View

3.
Fu Z, Smith P, Zhang L, Rubin M, Dunn R, Yao Z . Effects of raf kinase inhibitor protein expression on suppression of prostate cancer metastasis. J Natl Cancer Inst. 2003; 95(12):878-89. DOI: 10.1093/jnci/95.12.878. View

4.
Townsend J . Multifactorial experimental design and the transitivity of ratios with spotted DNA microarrays. BMC Genomics. 2003; 4(1):41. PMC: 239860. DOI: 10.1186/1471-2164-4-41. View

5.
Nakopoulou L, Vourlakou C, Zervas A, Tzonou A, Gakiopoulou H, Dimopoulos M . The prevalence of bcl-2, p53, and Ki-67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathologic correlates. Hum Pathol. 1998; 29(2):146-54. DOI: 10.1016/s0046-8177(98)90225-8. View